Oxford Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Oxford Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-589,440	Closed	-$2.18M	–	955
2016 Q1	$2.18M	Buy	589,440 +11,000	+2%	+$68.1K	0.06%	360
2015 Q4	$5.93M	Buy	578,440 +406,297	+236%	+$4.89M	0.14%	150
2015 Q3	$2.34M	Buy	+172,143	New	+$3.06M	0.07%	268
2014 Q2	–	Sell	-34,946	Closed	-$1.61M	–	846
2014 Q1	$1.61M	Sell	34,946 -122,276	-78%	-$7.17M	0.05%	401
2013 Q4	$11.2M	Sell	157,222 -26,582	-14%	-$2.03M	0.28%	83
2013 Q3	$15.8M	Sell	183,804 -84,225	-31%	-$7.14M	0.35%	40
2013 Q2	$17M	Buy	+268,029	New	+$14.2M	0.46%	22

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Oxford Asset Management's AEGR Position: Q2 2016 in Review

Oxford Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 589,440 shares — an estimated $2.18M sold.

Oxford Asset Management first reported a position in AEGR in Q2 2013 and held it in 7 quarters. The position peaked at $17M in Q2 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Oxford Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Oxford Asset Management sold 589,440 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $2.18M.
Oxford Asset Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Oxford Asset Management's Aegerion Pharmaceuticals position peaked at $17M in Q2 2013.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Oxford Asset Management's 13F filing for Q2 2016, filed 8 Aug 2016.